D-dimer-An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World.

IF 3.6 2区 医学 Q2 HEMATOLOGY Seminars in thrombosis and hemostasis Pub Date : 2024-10-17 DOI:10.1055/s-0044-1791700
Carolyne Elbaz, Martine J Hollestelle, Piet Meijer, Zachary Liederman, Rita Selby
{"title":"D-dimer-An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World.","authors":"Carolyne Elbaz, Martine J Hollestelle, Piet Meijer, Zachary Liederman, Rita Selby","doi":"10.1055/s-0044-1791700","DOIUrl":null,"url":null,"abstract":"<p><p>D-dimer assessment has several established roles in venous thromboembolism (VTE) and disseminated intravascular coagulation diagnosis, and recently the risk stratification of coronavirus disease 2019 (COVID-19). D-dimer assays are neither standardized nor harmonized, use varying methodologies, and use different reporting units, all resulting in a lack of interchangeability and generalizability of assays. Using large multiyear datasets from an international laboratory quality assurance program, we assessed (1) common D-dimer assays in use worldwide, (2) differences in analytical performance between different methods, and (3) interlaboratory variability between positive samples. External proficiency testing results from laboratories participating in the External Quality Control for Assays and Tests (ECAT) Foundation were analyzed from 2017 to 2023. Annually, between 578 and 690 laboratories participated in the D-dimer sample surveys with response rates ranging from 88 to 97%. The three most common assays in use in 2023 were the Siemens Innovance D-dimer (42%), the IL HemosIL D-dimer HS 500 (20%), and the Diagnostica Stago (Stago) Liatest D-dimer Plus (10%)-all these are automated, quantitative, latex immunoassays expressed in fibrinogen equivalent units (FEU). The highest interlaboratory variability was observed around the typical VTE exclusion threshold of 0.5 mg/L FEU. Lower interlaboratory variability was observed at values above 0.8 mg/L FEU. Our study provides recent, international performance data on currently used D-dimer assays and describes the significant variability between assays and across D-dimer concentrations. We demonstrate that assays are not interchangeable and that using them interchangeably has the potential to result in clinically important errors. There is an urgent need to educate users about these issues and to work towards harmonizing D-dimer units and reporting.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in thrombosis and hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1791700","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

D-dimer assessment has several established roles in venous thromboembolism (VTE) and disseminated intravascular coagulation diagnosis, and recently the risk stratification of coronavirus disease 2019 (COVID-19). D-dimer assays are neither standardized nor harmonized, use varying methodologies, and use different reporting units, all resulting in a lack of interchangeability and generalizability of assays. Using large multiyear datasets from an international laboratory quality assurance program, we assessed (1) common D-dimer assays in use worldwide, (2) differences in analytical performance between different methods, and (3) interlaboratory variability between positive samples. External proficiency testing results from laboratories participating in the External Quality Control for Assays and Tests (ECAT) Foundation were analyzed from 2017 to 2023. Annually, between 578 and 690 laboratories participated in the D-dimer sample surveys with response rates ranging from 88 to 97%. The three most common assays in use in 2023 were the Siemens Innovance D-dimer (42%), the IL HemosIL D-dimer HS 500 (20%), and the Diagnostica Stago (Stago) Liatest D-dimer Plus (10%)-all these are automated, quantitative, latex immunoassays expressed in fibrinogen equivalent units (FEU). The highest interlaboratory variability was observed around the typical VTE exclusion threshold of 0.5 mg/L FEU. Lower interlaboratory variability was observed at values above 0.8 mg/L FEU. Our study provides recent, international performance data on currently used D-dimer assays and describes the significant variability between assays and across D-dimer concentrations. We demonstrate that assays are not interchangeable and that using them interchangeably has the potential to result in clinically important errors. There is an urgent need to educate users about these issues and to work towards harmonizing D-dimer units and reporting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
D-二聚体--实验室检测质量的国际评估:在现实世界中使用二聚体的意义》。
D 二聚体评估在静脉血栓栓塞症(VTE)和弥散性血管内凝血诊断以及最近的 2019 年冠状病毒疾病(COVID-19)风险分层中发挥着多种既定作用。D 二聚体检测既没有标准化,也没有统一化,使用的方法各不相同,报告单位也各不相同,这些都导致检测结果缺乏互换性和通用性。我们利用国际实验室质量保证计划的大型多年数据集,评估了(1)全球使用的常见 D-二聚体检测方法,(2)不同方法之间分析性能的差异,以及(3)阳性样本之间的实验室间变异性。我们分析了从2017年到2023年参加化验和检测外部质量控制基金会(ECAT)的实验室的外部能力验证结果。每年有 578 至 690 家实验室参与 D-二聚体样本调查,回复率在 88% 至 97% 之间。2023 年最常用的三种检测方法是西门子 Innovance D-二聚体(42%)、IL HemosIL D-dimer HS 500(20%)和 Diagnostica Stago (Stago) Liatest D-dimer Plus(10%)--所有这些都是以纤维蛋白原当量单位(FEU)表示的自动化、定量乳胶免疫测定。在典型的 VTE 排除阈值 0.5 mg/L FEU 附近观察到的实验室间变异性最高。当数值高于 0.8 mg/L FEU 时,实验室间变异性较低。我们的研究提供了目前使用的 D-二聚体检测方法的最新国际性能数据,并描述了不同检测方法和不同 D-二聚体浓度之间的显著差异。我们的研究表明,检测方法不能互换,互换使用有可能导致临床上的重大误差。我们迫切需要让用户了解这些问题,并努力实现 D-二聚体单位和报告的统一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in thrombosis and hemostasis
Seminars in thrombosis and hemostasis 医学-外周血管病
CiteScore
8.80
自引率
21.10%
发文量
132
审稿时长
6-12 weeks
期刊介绍: Seminars in Thrombosis and Hemostasis is a topic driven review journal that focuses on all issues relating to hemostatic and thrombotic disorders. As one of the premiere review journals in the field, Seminars in Thrombosis and Hemostasis serves as a comprehensive forum for important advances in clinical and laboratory diagnosis and therapeutic interventions. The journal also publishes peer reviewed original research papers. Seminars offers an informed perspective on today''s pivotal issues, including hemophilia A & B, thrombophilia, gene therapy, venous and arterial thrombosis, von Willebrand disease, vascular disorders and thromboembolic diseases. Attention is also given to the latest developments in pharmaceutical drugs along with treatment and current management techniques. The journal also frequently publishes sponsored supplements to further highlight emerging trends in the field.
期刊最新文献
Coagulation abnormalities in chronic liver disease. Innovative Therapies for Acquired Hemophilia A. Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives. Patient Perspective on Disease Burden and Gene Therapy for Hemophilia A and B: The "Haemvolution for Patients" Italian Survey.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1